Aileron Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aileron Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Aileron Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.85M, a 220% decline year-over-year.
  • Aileron Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$29.2M, a 126% decline year-over-year.
  • Aileron Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.7M, a 42.4% increase from 2022.
  • Aileron Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$27.3M, a 4.45% decline from 2021.
  • Aileron Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$26.2M, a 4.26% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$29.2M -$5.85M -$4.02M -220% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$25.2M -$8.94M -$7.16M -400% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$18.1M -$7.11M -$2.33M -48.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$15.7M -$7.34M -$2.79M -61.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$12.9M -$1.83M +$4.54M +71.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$17.5M -$1.79M +$6.21M +77.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$23.7M -$4.78M +$3.64M +43.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$27.3M -$4.55M +$2.25M +33.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$29.6M -$6.37M +$336K +5.01% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-13
Q2 2022 -$29.9M -$7.99M -$2.31M -40.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-13
Q1 2022 -$27.6M -$8.42M -$1.45M -20.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-13
Q4 2021 -$26.2M -$6.8M -$1.87M -37.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$24.3M -$6.7M -$1.68M -33.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$22.6M -$5.69M -$1.3M -29.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-01
Q1 2021 -$21.3M -$6.98M -$227K -3.36% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-01
Q4 2020 -$21.1M -$4.93M +$2.31M +31.9% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-24
Q3 2020 -$23.4M -$5.02M +$2.73M +35.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$26.1M -$4.39M +$2.78M +38.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$28.9M -$6.75M +$464K +6.43% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$29.4M -$7.24M -$202K -2.87% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-24
Q3 2019 -$29.2M -$7.75M -$315K -4.24% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-24
Q2 2019 -$28.9M -$7.17M +$2.32M +24.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-24
Q1 2019 -$31.2M -$7.21M +$376K +4.96% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-24
Q4 2018 -$31.5M -$7.03M -$169K -2.46% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$31.4M -$7.43M -$1.18M -18.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-30
Q2 2018 -$30.2M -$9.49M -$4.57M -92.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-30
Q1 2018 -$25.6M -$7.59M -$3.03M -66.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-30
Q4 2017 -$22.6M -$6.87M -$2.42M -54.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-29
Q3 2017 -$20.2M -$6.26M -$2.04M -48.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-29
Q2 2017 -$18.1M -$4.92M +$611K +11% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-29
Q1 2017 -$18.8M -$4.56M -$632K -16.1% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-29
Q4 2016 -$18.1M -$4.44M Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$4.22M Jul 1, 2016 Sep 30, 2016 10-K 2018-04-02
Q2 2016 -$5.53M Apr 1, 2016 Jun 30, 2016 10-K 2018-04-02
Q1 2016 -$3.93M Jan 1, 2016 Mar 31, 2016 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.